SCHEMBL2643969

SCHEMBL2643969

Cc1noc(COc2cc(C(=O)O)cc3c2CC(C)(C)O3)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTP1 P09211 6/20 0.41
MAPT P10636 4/20 0.40
HSD17B10 Q99714 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.35
HPGD P15428 4/20 0.35
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
TP53 P04637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HIF1A Q16665 1/20 0.34
NPC1 O15118 2/20 0.34
TSHR P16473 2/20 0.34
MAPK1 P28482 2/20 0.34
RAB9A P51151 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
GAA P10253 2/20 0.34
CASP1 P29466 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2644593 0.86 KDM4E (0.32) GSTP1MAPTHSD17B10SMN1; SMN2HTT
SCHEMBL2645105 0.83 SMPD1 (0.35) HSD17B10HTTHPGDKDM4EALDH1A1
SCHEMBL2643790 0.83 NPC1 (0.50) MAPTHSD17B10SMN1; SMN2HTTHPGD
SCHEMBL642428 0.81 GCK (0.55) GSTP1MAPTHSD17B10HPGDKDM4E
SCHEMBL2644888 0.79 GCGR (0.36) HSD17B10HTTHPGDKDM4EALDH1A1
SCHEMBL2645457 0.78 KDM4A (0.37) MAPTHSD17B10SMN1; SMN2HTTHPGD
SCHEMBL2643933 0.78 TSHR (0.43) HSD17B10SMN1; SMN2HTTHPGDKDM4E
SCHEMBL643590 0.78 MAOB (0.49) SMN1; SMN2HPGDHIF1ANPC1RAB9A
SCHEMBL2643648 0.76 KDM5A (0.41) MAPTHSD17B10HTTHPGDKDM4E
SCHEMBL2645442 0.75 PIK3CA (0.33) MAPTHSD17B10SMN1; SMN2HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 GSTP1 1435/4885MAPT 3264/4885HSD17B10 1912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.